Phosphoproteomics in The Study of Cancer
Since the inception of phosphoproteomics, cancer research has focused on changes to the phosphoproteome during tumor development. Phosphoproteins could be cancer markers useful to cancer diagnostics and therapeutics. In fact, research has shown that there are distinct phosphotyrosine proteomes of breast and liver tumors. There is also evidence of hyperphosphorylation at tyrosine residues in breast tumors but not in normal tissues. Findings like these suggest that it is possible to mine the tumor phosphoproteome for potential biomarkers.
Increasing amounts of data are available suggesting that distinctive phosphoproteins exist in various tumors and that phosphorylation profiling could be used to fingerprint cancers from different origins. In addition, systematic cataloguing of tumor-specific phosphoproteins in individual patients could reveal multiple causative players during cancer formation. By correlating this experimental data to clinical data such as drug response and disease outcome, potential cancer markers could be identified for diagnosis, prognosis, prediction of drug response, and potential drug targets.
Read more about this topic: Phosphoproteomics
Famous quotes containing the words study and/or cancer:
“There are obvious places in which government can narrow the chasm between haves and have-nots. One is the public schools, which have been seen as the great leveler, the authentic melting pot. That, today, is nonsense. In his scathing study of the nation’s public school system entitled “Savage Inequalities,” Jonathan Kozol made manifest the truth: that we have a system that discriminates against the poor in everything from class size to curriculum.”
—Anna Quindlen (b. 1952)
“We “need” cancer because, by the very fact of its incurability, it makes all other diseases, however virulent, not cancer.”
—Gilbert Adair, British author, critic. “Under the Sign of Cancer,” Myths and Memories (1986)